U
LIR Life Sciences Corp. SKNY
CNSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
--
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

07/31/2025 07/31/2024
Total Cash And Short-Term Investments 1.90K --
Total Receivables 8.80K --
Inventory -- --
Prepaid Expenses -- --
Finance Division Loans and Leases Current -- --
Total Finance Division Other Current Assets -- --
Other Current Assets -- --
Total Current Assets 10.70K --

Total Current Assets 10.70K --
Net Property, Plant & Equipment -- --
Long-term Investments -- --
Goodwill -- --
Total Other Intangibles 75.10K --
Finance Div Loans & Leases LT -- --
Total Finance Div Other LT Assets -- --
Total Other Assets -- --
Total Assets 85.90K --

Total Accounts Payable 271.20K --
Total Accrued Expenses -- --
Short-term Debt 25.30K --
Current Portion of Long-Term Debt/Capital Leases -- --
Finance Division Debt Current -- --
Total Finance Division Other Current Liabilities -- --
Total Other Current Liabilities -- --
Total Current Liabilities 296.50K --

Total Current Liabilities 296.50K --
Long-Term Debt -- --
Short-term Debt 25.30K --
Capital Leases -- --
Finance Division Debt Non Current -- --
Total Finance Division Other Non Current Liabilities -- --
Total Other Liabilities -- --
Total Liabilities 296.50K --

Common Stock & APIC 216.70K --
Retained Earnings -427.40K --
Treasury Stock & Other -- --
Total Common Equity -210.70K --

Preferred Stock Redeemable -- --
Preferred Stock Non Redeemable -- --
Preferred Stock Convertible -- --
Preferred Stock, Others -- --
Total Preferred Equity -- --

Total Common Equity -210.70K --
Total Preferred Equity -- --
Total Minority Interest -- --
Total Equity -210.70K --